Results 1 to 10 of about 30,028 (235)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia [PDF]

Journal of the American Heart Association, 2019
F amilial hypercholesterolemia (FH) is a common yet underdiagnosed autosomal dominant disorder that affects 1 in 220 individuals globally. FH is characterized by lifelong elevation of low-density lipoprotein cholesterol (LDL-C) and if untreated leads to ...
, Seyed Hamed Hosseini Dehkordi, Patrick M Moriarty   +2 more
exaly   +8 more sources

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia [PDF]

New England Journal of Medicine, 2020
Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50% but ...
Frederick J Raäl, Kausik K Ray, Traci Turner   +2 more
exaly   +9 more sources

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia [PDF]

New England Journal of Medicine, 2020
Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels. Its effects in pediatric patients with heterozygous familial hypercholesterolemia are not known.We conducted a 24-week, randomized, double-blind ...
Santos, Raul D., Ruzza, Andrea, Hovingh, G. Kees, Wiegman, Albert, Mach, François, Kurtz, Christopher E., Hamer, Andrew, Bridges, Ian, Bartuli, Andrea, Bergeron, Jean, Szamosi, Tamás, Santra, Saikat, Stefanutti, Claudia, Descamps, Olivier S., Greber-Platzer, Susanne, Luirink, Ilse, Kastelein, John J.P., Gaudet, Daniel, HAUSER-RCT INVESTIGATORS, Stéphenne, Xavier, Sokal, Etienne   +20 more
semanticscholar   +8 more sources

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside [PDF]

Drug Design, Development and Therapy, 2021
Anandita Agarwala,1 Renato Quispe,2 Anne C Goldberg,3 Erin D Michos2 1Division of Cardiology, Baylor Scott and White Health, Heart Hospital Baylor Plano, Plano, TX, USA; 2Ciccarone Center for the Prevention of Cardiovascular Disease, Division of ...
Agarwala A, Quispe R, Goldberg AC, Michos ED   +3 more
doaj   +3 more sources

Asymptomatic Intracranial Artery Stenosis/Occlusion in Heterozygous Familial Hypercholesterolemia: Its Frequency and Implications for Cerebrovascular and Cardiovascular Events [PDF]

Journal of the American Heart Association
Background The atherogenic characteristics of heterozygous familial hypercholesterolemia (HeFH) increase the risk of premature atherosclerotic cardiovascular disease including not only coronary artery disease but ischemic stroke.
Sayaka Funabashi, Yu Kataoka, Mika Hori   +2 more
exaly   +4 more sources

Coronary Artery and Carotid Artery Plaques in Patients With Heterozygous Familial Hypercholesterolemia [PDF]

JACC Adv, 2023
Background Little is known regarding the formation of coronary and carotid plaques and their impact on cardiovascular disease in patients with familial hypercholesterolemia (FH). Objectives This study aimed to determine: 1) if the development of coronary
Tada H, Nohara A, Usui S, Sakata K, Hayashi K, Fujino N, Kawashiri M, Takamura M.   +7 more
europepmc   +2 more sources

Polygenic Background Modifies Risk of Coronary Artery Disease Among Individuals With Heterozygous Familial Hypercholesterolemia [PDF]

JACC Adv, 2023
Background Heterozygous familial hypercholesterolemia (HeFH) is a monogenic disorder characterized by increased circulating low-density lipoprotein cholesterol and accelerated atherosclerosis.
Reeskamp L, Shim I, Dron J, Ibrahim S, Tromp T, Fahed A, Patel A, Hutten B, Stroes E, Hovingh G, Khera A.   +10 more
europepmc   +2 more sources

Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). [PDF]

BMC Med, 2023
Background Heterozygous familial hypercholesterolemia (HeFH) is largely underdiagnosed and undertreated in China where few patients achieved recommended target levels of low density lipoprotein cholesterol (LDL-C).
Chai M, He Y, Zhao W, Han X, Zhao G, Ma X, Qiao P, Shi D, Liu Y, Han W, An P, Li H, Yan S, Ma Q, Deng H, Qian L, Zhou Y, CREDIT-2 investigators.   +17 more
europepmc   +2 more sources

The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study. [PDF]

J Pers Med, 2021
Heterozygous familial hypercholesterolemia (HeFH) is one of the most common genetic conditions but remains substantially underdiagnosed. The aim of our study was to investigate the prevalence of HeFH in the population of 11 different regions of Russia ...
Meshkov AN, Ershova AI, Kiseleva AV, Shalnova SA, Drapkina OM, Boytsov SA, On Behalf Of The Fh-Esse-Rf Investigators.   +6 more
europepmc   +2 more sources

Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study [PDF]

Lipids in Health and Disease, 2022
Background Heterozygous familial hypercholesterolemia (HeFH) due to low-density lipoprotein receptor (LDLR) mutations predisposes patients to highly elevated levels of cholesterol, and patients are at increased risk of adverse cardiovascular events and ...
Kasper Aalbæk Kjærgaard, Sixten Harborg, Henrik Kjærulf Jensen, Signe Borgquist   +3 more
doaj   +2 more sources